{"title":"OP153 Access To Real-World Data For Use In Health Technology Assessment – Still Work To Be Done","authors":"Christian Ritz, Hansoo Kim","doi":"10.1017/s0266462323001526","DOIUrl":null,"url":null,"abstract":"IntroductionReal-world data (RWD) is an important source of evidence for health technology assessment (HTA). It is widely used to fill clinical trial data gaps and to inform risk-sharing agreements. HTA is mandatory in many jurisdictions as it is used for price negotiation between a manufacturer and a payer. HTA practitioners have so far had limited involvement in the debate surrounding access to RWD as regulators have primarily focused on scientific research and market authorization. This study examined the challenges of obtaining RWD for HTA decision-making that is beneficial at the population level when data sources are restricted to maintain the data integrity and rights of the public.MethodsTypes of RWD and processes for obtaining data were assessed for two jurisdictions (Australia and Denmark). Types of data considered were national registries, ongoing or completed cohorts, surveys at various universities, archived historical data, and medical claims data. The assessment was performed by analyzing a series of cases.ResultsThere were similarities and differences between the two jurisdictions. In both jurisdictions the process for obtaining data included an ethics application as well as data handling fees. Patients and clinicians had little to no say in what their data are used for. It can take up to six months to obtain data. Person identification numbers enable linking of different datasets. Population wide data are accessible in Denmark only through secure servers, whereas full data sets, such as prescription data, can be released for research in Australia. Public hospital data, such as electronic health records, are not easily obtained in Denmark. In Australia, public hospitals are run by individual states and, therefore, additional effort is required to access nationwide data.ConclusionsAccess to RWD for HTA is challenging in both Australia and Denmark. Improvements in the process of applying for data and linking different data sources for HTA purposes are still needed.","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Technology Assessment in Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/s0266462323001526","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
IntroductionReal-world data (RWD) is an important source of evidence for health technology assessment (HTA). It is widely used to fill clinical trial data gaps and to inform risk-sharing agreements. HTA is mandatory in many jurisdictions as it is used for price negotiation between a manufacturer and a payer. HTA practitioners have so far had limited involvement in the debate surrounding access to RWD as regulators have primarily focused on scientific research and market authorization. This study examined the challenges of obtaining RWD for HTA decision-making that is beneficial at the population level when data sources are restricted to maintain the data integrity and rights of the public.MethodsTypes of RWD and processes for obtaining data were assessed for two jurisdictions (Australia and Denmark). Types of data considered were national registries, ongoing or completed cohorts, surveys at various universities, archived historical data, and medical claims data. The assessment was performed by analyzing a series of cases.ResultsThere were similarities and differences between the two jurisdictions. In both jurisdictions the process for obtaining data included an ethics application as well as data handling fees. Patients and clinicians had little to no say in what their data are used for. It can take up to six months to obtain data. Person identification numbers enable linking of different datasets. Population wide data are accessible in Denmark only through secure servers, whereas full data sets, such as prescription data, can be released for research in Australia. Public hospital data, such as electronic health records, are not easily obtained in Denmark. In Australia, public hospitals are run by individual states and, therefore, additional effort is required to access nationwide data.ConclusionsAccess to RWD for HTA is challenging in both Australia and Denmark. Improvements in the process of applying for data and linking different data sources for HTA purposes are still needed.
期刊介绍:
International Journal of Technology Assessment in Health Care serves as a forum for the wide range of health policy makers and professionals interested in the economic, social, ethical, medical and public health implications of health technology. It covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. In addition to general essays and research reports, regular columns on technology assessment reports and thematic sections are published.